MannKind Corporation (NASDAQ:MNKD)’s AFREZZA: one of its kind
Recently, MannKind Corporation (NASDAQ:MNKD) completed a phase-III study on Afrezza, its diabetes candidate. All the follow-up visits for the patients who had enrolled in the study, were completed. MNKD expects to publish all the data from the study towards the end of summer. The open-label phase-III study evaluated the inhalation powder, Afrezza in patients who suffer from type II diabetes. The company is at a level of creating a nourishment blood insulin treatment, AFREZZA, that is beneficial for treating 1 or 2 Type diabetes patients.
What is Type 1 and Type 2 diabetes?
Type 1 diabetes develops in the body when the insulin-producing cells are destroyed and the body is not able to produce any insulin. Insulin opens up the path to cells in the body. Once the path has been opened up, it is possible for glucose to enter the cells, where it then gets used as fuel. In those who suffer from Type 1 diabetes the body is not able to produce any insulin. This means the path to the cells cannot be opened up. Consequently there is a build-up of glucose in the blood. This kind of diabetes may develop at any age though it generally appears during childhood and before a person touches the age of 40.
On the other hand, Type 2 diabetes develops in the body when it is still able to produce a certain amount of insulin, which is not sufficient though. In other cases, the patient suffers from insulin resistance, which is when the insulin doesn’t work the way it should. This also leads to glucose build-up. Type 2 diabetes generally makes an appearance in people above the age of 40.
The genetics factor
It is troubling to note that in the U.S alone, in 2012, 22.3M people were living with either type 1 or type 2 diabetes compared to 17.5M during 2007. Unfortunately, it is not possible to control all diabetes risk factors. African-Americans, Asian-Americans and American Indians are at a higher diabetes risk than Caucasians. This has led researchers to believe that a genetic link exists. MannKind Corporation (NASDAQ:MNKD) is one of the companies that has been consistent with its development of diabetes drugs.